Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The US drug regulator has given the nod to Pfizer's Covid treatment pill Paxlovid, making it the first oral antiviral drug cleared during the pandemic. The medication, which is recommended for people at a high risk of developing severe Covid-19, could be available to patients as early as this weekend in the United States. Pfizer’s pill was cleared for use in people age 12 and up who weigh at least 40 kilograms.The U.S. has purchased 10 million courses of Pfizer’s treatment, Paxlovid, in a $5 billion deal in an effort to reach out to the unvaccinated population at risk from the rising Omicron variant. Experts expect the FDA to give the nod for Merck's pill also this week. The authorization comes at a crucial turning point in the pandemic, as hospital systems across the U.S. have been battered by a wave of delta infections, and are now bracing for another wave of patients infected with the highly contagious omicron variant. There were over 170,000 new cases of Covid in the US on Tuesday. 

Pfizer's Covid pill gets a nod from USFDA, what we know about it

The U.S. has purchased 10 million courses of Pfizer’s treatment, Paxlovid, in a $5 billion deal in an effort to reach out to the unvaccinated population at risk from the rising Omicron variant. Experts expect the FDA to give the nod for Merck's pill also this week. 

A pill for covid gets nod from US drug regulator

<ul>
<li>USFDA&nbsp;gives permission to use Pfizer's Covid&nbsp;pill&nbsp;</li>
<li>First oral antiviral drug cleared during the pandemic</li>
<li>US drug regulator likely to give nod to Merck's Covid&nbsp;pill this week as well</li>
<li>US facing surge of Omicron cases, 73% of fresh infections from new variant</li>
</ul>

The medication, which is recommended for people at a high risk of developing severe&nbsp;Covid-19, could be available to patients as early as this weekend in the US.

The US drug regulator has given the nod to Pfizer's&nbsp;Covid treatment pill Paxlovid, making it the first oral antiviral drug cleared during the pandemic.&nbsp;The medication, which is recommended for people at a high risk of developing severe&nbsp;Covid-19, could be available to patients as early as this weekend in the United States. Pfizer&rsquo;s pill was cleared for use in people age 12 and up who weigh at least 40 kilograms. The U.S. has purchased 10 million courses of Pfizer&rsquo;s treatment, Paxlovid, in a $5 billion deal in an effort to reach out to the unvaccinated&nbsp;population at risk from the rising Omicron variant.&nbsp;Experts expect the FDA to give the nod for Merck's pill also this week.&nbsp;
Also watch:&nbsp;<a href="https://www.editorji.com/world-news/britain-clears-merck-s-pill-to-treat-covid-19-here-s-all-you-need-to-know-about-molnupiravir-1636029679595" target="_blank">Britain clears Merck's pill to treat Covid-19: here's all you need to know about molnupiravir</a> The authorization comes at a crucial turning point in the pandemic, as hospital systems across the U.S. have been battered by a wave of delta infections, and are now bracing for another wave of patients infected with the highly contagious omicron variant. There were over 170,000 new cases of Covid&nbsp;in the US on Tuesday.&nbsp;

Covid booster shot has got a nod from the United States drug regulator.&nbsp;The Food and Drug Administration authorized a booster dose of Pfizer and BioNTech's Covid-19 vaccine for people 65 and older and for certain high-risk adult population. Booster doses can be given any time at least six months after a person received their second shot, the FDA said in a&nbsp;statement.Pfizer said In documents made public last week that an observational study in Israel showed a third dose of the Covid vaccine six months after a second shot restores protection from infection to 95%.
Though Americans 65 and older make up roughly 17% of the U.S. population, they account for more than 77% of all Covid deaths, according to the Centers for Disease Control and Prevention.The Centers for Disease Control and Prevention&rsquo;s Advisory Committee on Immunization Practices is expected to meet Thursday to make its own recommendations about who should receive the additional dose.&nbsp;

Covid booster: US FDA gives nod to Pfizer for booster for 65+ and high risk people

Move aside third wave, the third dose is here! USFDA authorizes booster shots of the Pfizer Covid&nbsp;19 vaccine. Find out who is eligible and how effective is it really going to be?

Covid Booster| US FDA approves Pfizer's booster shot 

The emergency-use authorization also allows boosters for people 18 and older whose occupational exposure to the&nbsp;virus puts them at elevated risk of serious complications

Covid booster shot has got a nod from the United States drug regulator.&nbsp;The Food and Drug Administration authorized a booster dose of Pfizer and BioNTech's Covid-19 vaccine for people 65 and older and for certain high-risk adult population. Booster doses can be given any time at least six months after a person received their second shot, the FDA said in a&nbsp;statement. Pfizer said In documents made public last week that an observational study in Israel showed a third dose of the Covid vaccine six months after a second shot restores protection from infection to 95%.
Though Americans 65 and older make up roughly 17% of the U.S. population, they account for more than 77% of all Covid deaths, according to the Centers for Disease Control and Prevention. The Centers for Disease Control and Prevention&rsquo;s Advisory Committee on Immunization Practices is expected to meet Thursday to make its own recommendations about who should receive the additional dose.&nbsp;

usfda

Categories